StreetInsider.com News Articles

Radnostix and Nano Nuclear file NRC letter of intent for license transfer

Mon, 19 Oct 2026 08:07:12 -0400

Radnostix, Inc. (OTCQB: INIS), formerly International Isotopes Inc., and Nano Nuclear Energy have jointly submitted a Letter of Intent to the U.S. Nuclear Regulatory Commission seeking consent for the transfer of NRC Material License SUB-1011, according to a press release.

The filing requests NRC consent under 10 CFR 40.46 for the transfer of License SUB-1011 from Radnostix and its subsidiary International Isotopes Fluorine Products, Inc. to Nano Nuclear's wholly owned subsidiary, HALEU Energy Fuel Inc. The parties plan to follow the letter with a formal consent application. NRC consent is a required closing condition of an asset purchase agreement signed Sept.

Radnostix and NANO Nuclear Energy Announce Joint Submission of Letter of Intent to NRC Seeking Consent for Transfer of License SUB-1011, Following Lea County Approval of Property LOI

Mon, 19 Oct 2026 08:05:00 -0400

IDAHO FALLS, Idaho, Oct. 19, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company") today announced that they have jointly submitted a Letter of Intent to the U.S. Nuclear Regulatory Commission (NRC) seeking the NRC's consent for the transfer of ownership of NRC Material License SUB-1011 in connection with the previously announced asset purchase agreement.

Radnostix and NANO Nuclear Energy Announce Joint Submission of Letter of Intent to NRC Seeking Consent for Transfer of License SUB-1011, Following Lea County Approval of Property LOI

Mon, 19 Oct 2026 08:05:00 -0400

Radnostix to sell nuclear fuel assets to Nano Nuclear for $13.5M

Thu, 01 Oct 2026 08:31:26 -0400

Radnostix, Inc. (OTCQB: INIS), formerly International Isotopes Inc., has signed a definitive asset purchase agreement to sell its U.S. nuclear fuel processing assets to Nano Nuclear Energy Inc. (NASDAQ: NNE) and its subsidiary HALEU Energy Fuel Inc. for a combined $13.5 million, according to a press release dated Oct. 1, 2026.

The assets being divested include a U.S. Nuclear Regulatory Commission (NRC) 10 CFR Part 40 license, patented technology, engineering and safety analyses, regulatory and permitting materials, equipment, and historical project development records associated with depleted uranium hexafluoride (DUF6) deconversion and fluorine extraction. The license was originally issued for a proposed

Radnostix to sell nuclear fuel assets to Nano Nuclear for $13.5M

Thu, 01 Oct 2026 08:31:26 -0400

Radnostix Signs Definitive Agreement to Divest DUF6 and Fluorine Assets to NANO Nuclear

Thu, 01 Oct 2026 08:30:00 -0400

BOISE, Idaho, Oct. 1, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ( "Radnostix" or the "Company") today announced that Radnostix and its wholly-owned subsidiary, International Isotopes Fluorine Products, Inc, have entered into a definitive asset purchase agreement with NANO Nuclear Energy Inc. (NASDAQ: NNE) and its wholly-owned subsidiary, HALEU Energy Fuel Inc., (collectively "NANO"), to divest its U.S. nuclear fuel processing assets, including

Radnostix Signs Definitive Agreement to Divest DUF6 and Fluorine Assets to NANO Nuclear

Thu, 01 Oct 2026 08:30:00 -0400

Radnostix Signs Definitive Agreement to Divest DUF6 and Fluorine Assets to NANO Nuclear

Thu, 01 Oct 2026 08:30:00 -0400

Radnostix Signs Definitive Agreement to Divest DUF6 and Fluorine Assets to NANO Nuclear

Thu, 01 Oct 2026 08:30:00 -0400

Form 8-K RADNOSTIX INC For: Sep 28

Thu, 01 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27131834.html

Form S-8 RADNOSTIX INC

Wed, 26 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260826/26982559.html

Form S-8 RADNOSTIX INC

Wed, 26 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260826/26982559.html

Radnostix revenue falls 27% amid product recalls and FDA actions

Thu, 13 Aug 2026 11:02:25 -0400

Radnostix, Inc. (OTCQB: INIS), formerly International Isotopes Inc., reported a 27% decline in revenue for the second quarter ended June 30, 2026, citing the residual effects of two voluntary product recalls and a Cobalt Products shutdown.

Total revenue for the quarter was $2.67 million, down from $3.66 million in the same period a year earlier. For the first six months of 2026, revenue was $5.05 million compared with $6.89 million in the prior-year period. The net loss for the quarter widened to $882,000 from $161,000 in Q2 2025. The six-month net loss reached $2.23 million versus $273,000 in the first half

Radnostix revenue falls 27% amid product recalls and FDA actions

Thu, 13 Aug 2026 11:02:25 -0400

Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition

Thu, 13 Aug 2026 11:02:00 -0400

IDAHO FALLS, Idaho, Aug. 13, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its financial results for the second quarter and six months ended June 30, 2026 and the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission.

Second Quarter and First Half 2026 Financial and Operational Summary

Total revenue for the three months ended June 30, 2026 was $2.67 million, a 27%

Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition

Thu, 13 Aug 2026 11:02:00 -0400

Second Quarter and First Half 2026 Financial and Operational Summary

Total revenue for the three months ended June 30, 2026 was $2.67 million, a 27%

Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition

Thu, 13 Aug 2026 11:02:00 -0400

Second Quarter and First Half 2026 Financial and Operational Summary

Total revenue for the three months ended June 30, 2026 was $2.67 million, a 27%

Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition

Thu, 13 Aug 2026 11:02:00 -0400

Second Quarter and First Half 2026 Financial and Operational Summary

Total revenue for the three months ended June 30, 2026 was $2.67 million, a 27%

Form 10-Q RADNOSTIX INC For: Jun 30

Wed, 12 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260812/26914305.html

Form 10-Q RADNOSTIX INC For: Jun 30

Wed, 12 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260812/26914305.html

Form 8-K RADNOSTIX INC For: Jul 16

Tue, 21 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260721/26796310.html

Form 8-K RADNOSTIX INC For: Jul 16

Tue, 21 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260721/26796310.html

Radnostix acquires Lucerno Dynamics assets for radiopharma portfolio

Thu, 02 Jul 2026 10:43:28 -0400

Radnostix, Inc. (OTCQB: INIS) announced the closing of its acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform, the ELLEXA® Explorer software, and associated intellectual property, according to a press release dated July 2, 2026.

The LARA System was developed to identify extravasations of intravenously administered radiopharmaceuticals and improve dosimetry. The product line has since expanded to include a real-time visualization feature intended to allow clinicians to detect extravasations during theranostics administration. According to Lucerno Dynamics CEO Ron Lattanze, the system has been used in nearly 50,000 administrations across facilities in Australia, Singapore, Japan, Europe, and

Radnostix acquires Lucerno Dynamics assets for radiopharma portfolio

Thu, 02 Jul 2026 10:43:28 -0400

Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio

Thu, 02 Jul 2026 10:42:00 -0400

IDAHO FALLS, Idaho, July 2, 2026 /PRNewswire/ -- Radnostix, Inc. (OTCQB: INIS) ("Radnostix" or the "Company"), a leader in radioisotope production and nuclear medicine solutions, today announced the successful closing of its acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform, ELLEXA® Explorer software and associated intellectual property.

The product line was originally developed to identify, improve dosimetry of, and reduce the frequency of extravasations of IV administered radiopharmaceuticals. Recently, the product line expanded to include a Real-Time Visualization feature. Clinicians can now stop extravasations as they